Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* A positive histological diagnosis of UC ≥3 months prior to entry into the study. If a histological diagnosis is not available but all signs and symptoms suggest UC, the subject's eligibility should be discussed with Pfizer.~* Active UC as defined by a score of ≥6 on the Mayo score.~* An endoscopic (by flexible sigmoidoscopy) sub-score of ≥2 on the Mayo score determined within 7 days of first dosing.~Exclusion Criteria:~* Subjects with UC, which is confined to a proctitis on a flexible sigmoidoscopy.~* Subjects who have had surgery as a treatment for UC or are likely to require surgery within the duration of the study.~* Subjects displaying clinical signs of ischemic colitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 0.03 mg/kg or placebo iv (Type: OTHER): None
- 0.1 mg/kg or placebo iv (Type: OTHER): None
- 0.3 mg/kg or placebo iv (Type: OTHER): None
- 1.0 mg/kg or placebo iv (Type: EXPERIMENTAL): None
- 3.0 mg/kg or placebo sc (Type: OTHER): None
- 10 mg/kg or placebo iv (Type: OTHER): None
- 0.3 mg/kg or placebo sc (Type: OTHER): None
- 0.1 mg/kg or placebo iv (multiple dose) (Type: OTHER): None
- 0.3 mg/kg or placebo iv (multiple dose) (Type: OTHER): None
- 3.0 mg/kg or placebo iv (Type: OTHER): None
- 0.1 mg/kg or placebo sc (Type: OTHER): None
- 0.3 mg/kg or placebo sc (multiple dose) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).